Antibody biotech Diagonal Therapeutics lands $128M to pursue rare diseases

03 Apr 2024

ADC

Diagonal Therapeutics has launched with $128 million to go after an orphan disease that leads to chronic anemia, and another antibody for the same rare disease that is also targeted by Merck’s newly approved drug , Winrevair. Just last week, the biotech was congratulating its chief scientific officer on his contributions to the same Merck drug. The Cambridge, MA-based biotech came out of stealth on Wednesday morning with the seed and Series A funds from blue-chip backers like BVF Partners and Atlas Venture. Additional investors include Lightspeed Venture Partners, RA Capital Management, Frazier Life Sciences, Viking Global Investors , Velosity Capital and Checkpoint Capital.

For more details,please visit the original website

The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.

Organizations

Antibody Biopharm, Inc.Diagonal Therapeutics, Inc.

Merck & Co., Inc.

[+3]

Indications

Anemia

Targets

Drugs

Sotatercept

Hot reports

Global Drug R&D Express (Apr 2024)

PatSnap Synapse

Global Drug R&D Express (Mar 2024)

PatSnap Synapse

Global Drug R&D Express (Feb 2024)

PatSnap Synapse

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.